KAHR Medical Ltd.

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

The month of March began with multiple venture capital mega-rounds of $100m or more, led by Immunocore Ltd. ’s $130m series B round at the start of the week, which included large rounds for [Akouos I

In an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure – and the limitations – of strategic pharma-VC relationships. By Ch